Michael A. Klufas, MD, discusses issues with off-label bevacizumab use, focusing on compounding issues and decreases in clinical efficacy due to repackaging.
Expert retina specialists review the impact of biosimilars in clinical ophthalmology practice, highlighting the potential decrease of financial burden to the patient.